Can sotoracib (AMG510) treat lung squamous cell carcinoma?

Sotoracib (AMG510) is a targeted drug targeting KRAS G12C mutant tumors. It has shown significant efficacy in non-small cell lung cancer (NSCLC) in clinical trials. However, due to the prevalence of KRAS mutations in multiple tumor types, including lung squamous cell carcinoma, sotoracib may also have certain therapeutic potential for these patients. However, data on the specific efficacy and safety of sotoraxib in the treatment of lung squamous cell carcinoma are still limited. Therefore, more clinical trials and studies are needed to verify its efficacy and safety before using this drug to treat lung squamous cell carcinoma. At the same time, sotoraxib is a prescription drug, and you should follow your doctor's advice and guidance before use.